News

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is proud to announce the designation of a new CMTA Center of ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is thrilled to announce the designation of a new CMTA Center of ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is excited to announce it has awarded the CMTA Center of Excellence ...

Exciting progress from CMTA’s Strategy To Accelerate Research (STAR) program is once again highlighted with a recent publication celebrating a decade of CMT genomics discovery made possible by the GENESIS platform. This critically important CMTA-funded work, published in Experimental Neurology, ...

The Charcot-Marie-Tooth Association (CMTA) congratulates CMTA-STAR Alliance Partner NMD Pharma A/S (NMD Pharma) on initiating its Phase II SYNAPSE-CMT trial. This significant milestone reflects a shared commitment to advancing therapeutic options for individuals living with CMT. The trial’s first patient ...